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1A cornerstone of atherosclerotic cardiovascular disease (ASCVD) risk reduction, statin therapy has consis-
tently lowered cardiovascular disease (CVD) events in mul-
tiple randomized controlled trials during the past 30 years.1 
Cholesterol treatment guidelines from the American College 
of Cardiology/American Heart Association (ACC/AHA) pub-
lished in 2013 recommend moderate-to-high intensity statins 
for primary prevention in adults who have increased cardiac 
risk; defined as having a 10-year ASCVD risk score of ≥7.5% 
based on the ACC/AHA pooled cohort risk equation calcula-
tor.2 The ASCVD risk score is based on traditional CVD risk 
factors, such as the presence of diabetes mellitus, hyperten-
sion, and smoking history.
See Editorial by Grinspoon and Hoffmann 
See Clinical Perspective
Since their release, these recommendations have created 
controversy surrounding the accuracy and appropriateness of 
applying the calculator to special populations, such as those 
with HIV. Although CVD mortality has decreased for the gen-
eral population in the United States during the past decade, 
partly because of the treatment of modifiable risk factors, such 
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as hyperlipidemia, the HIV-infected population has seen an 
increase in CVD mortality during the same period.3 Although 
the increased cardiac risk seen in HIV-infected adults is partly 
attributed to traditional factors, such as smoking, a grow-
ing body of evidence has shown that there are HIV-specific 
issues, such as antiretroviral therapy-related dyslipidemia and 
chronic inflammation, that independently contribute to the 
elevated risk.4
Given the potential influence of nontraditional factors on 
CVD risk in HIV-infected adults, applying the ACC/AHA 
pooled cohort risk equation calculator to HIV-infected adults 
may underestimate their CVD risk and subsequently fail to 
recommend statin therapy. The ACC/AHA cholesterol guide-
lines suggest using additional risk-assessment tools, such as 
noninvasive atherosclerosis imaging, to help guide statin treat-
ment decisions in special populations. Carotid atherosclero-
sis by ultrasound has been shown to predict future ASCVD 
events and can be used as a surrogate measure to assess the 
vascular benefits of statin therapy.5 Beyond using traditional 
risk factors, the detection of carotid atherosclerosis by ultra-
sound may help identify a subset of HIV-infected adults who 
are at increased CVD risk and may benefit from treatment. 
The aim of our current study is to assess the application of 
the ACC/AHA cholesterol treatment guidelines on a cohort 
of HIV-infected adults who have had an evaluation of carotid 
atherosclerosis by ultrasound.
Patients and Methods
Participants
Study participants were followed at San Francisco General Hospital 
and San Francisco Veteran’s Affairs Medical Center as part of the 
SCOPE (Studies of the Consequences of the Protease Inhibitor 
Era) cohort—a longitudinal observational cohort of HIV-infected 
individuals. Participants with a history of established ASCVD, in-
cluding coronary heart disease, cerebral vascular disease, or periph-
eral vascular disease or a history of prior and current statin use, 
were excluded from the study. The study follow-up period began 
in 2001, and participants were seen annually. The University of 
California, San Francisco Committee on Human Research ap-
proved this study, and all participants provided written informed 
consent (NCT01519141). For all-cause mortality, participants 
were followed through January 2015 or until the time of death as 
determined by the National Death Index. Two independent physi-
cians adjudicated cardiovascular death using patient International 
Classification of Diseases-Ninth Revision codes provided by the 
National Death Index. To be considered a cardiovascular death, 
patients were required to have an International Classification of 
Diseases-Ninth Revision code related to cardiovascular pathology 
in ≥1 of the first 3 International Classification of Diseases-Ninth 
Revision codes reported on the death document.
Clinical and Laboratory Assessment
Interviews and structured questionnaires were given to all partici-
pants at the time of enrollment covering sociodemographic charac-
teristics, CVD risk factors, HIV disease history, medications, and 
health-related behaviors, including drug use. Fasting blood work 
was drawn to measure serum total cholesterol, triglycerides, and 
high-density lipoprotein (HDL) cholesterol. Low-density lipopro-
tein (LDL) cholesterol was calculated using Friedewald formula6 
except for participants with triglycerides ≥400 or <40 mg/dL, 
where it was measured directly. High-sensitivity C-reactive protein 
levels were measured using a high-sensitivity assay (Dade Behring, 
Deerfield, IL).
ASCVD Risk Assessment and Statin Recommendation
Statin recommendation for primary prevention was assessed for each 
participant using the 2004 Adult Treatment Panel (ATP) III and 2013 
ACC/AHA cholesterol treatment guidelines.2,7 Using ATP III, partici-
pants were recommended for statin therapy if they were considered to 
have (1) diabetes mellitus or a 10-year Framingham risk score (FRS) 
>20% and LDL ≥100 mg/dL, (2) 2+ CVD risk factors or 10-year 
FRS 10% to 20% and LDL ≥130 mg/dL, (3) 2+ CVD risk factors 
or 10-year FRS <10% and LDL ≥160 mg/dL, or (4) 0 to 1 CVD risk 
factors with LDL ≥190 mg/dL. FRS was calculated using the follow-
ing variables: age, sex, total cholesterol, HDL cholesterol, smoking 
status, systolic blood pressure, and currently on high blood pressure 
medications.7 Risk factors included hypertension, smoking, low HDL 
cholesterol (<40 mg/dL), family history of premature coronary heart 
disease (coronary heart disease in men first-degree relative <55 years 
of age; coronary heart disease in women first degree-relative <65 
years of age), and age (men ≥45 years; women ≥55 years). Using 
ACC/AHA guidelines, statins were recommended for participants if 
they were (1) ≥21 years of age with LDL levels ≥190 mg/dL, (2) 40 
to 75 years old with diabetes mellitus with LDL cholesterol 70 to 
189 mg/dL, or (3) 40 to 75 years of age with ASCVD risk score of 
≥7.5% using the ACC/AHA risk calculator. ACC/AHA risk calcula-
tor included the following variables: age, sex, total cholesterol, HDL 
cholesterol, smoker, systolic blood pressure, current treatment with 
blood pressure medications, diabetes mellitus, and race (white, black, 
or other).2
Carotid Atherosclerosis Assessment
Carotid artery intima-media thickness (CIMT) was assessed using the 
GE Vivid 7 system and a 10-MHz linear array probe and measured in 
12 segments, including the near and far wall of the common carotid 
artery, bifurcation, and internal carotid artery of both the right and 
left carotid arteries, according to the standard protocol from the ARIC 
Study (Atherosclerosis Risk in Communities Study)8 and as previous-
ly described from our group.9,10 All measurements were performed by 
one experienced technician on digital images using a manual caliper. 
The technician was blinded with respect to regard to patient history 
and clinical characteristics. Carotid plaque was defined as a focal area 
with IMT >1.5 mm in any segment. Repeat scans and measurements 
were performed with a noted variation coefficient—the ratio of the 
standard deviation to the mean—of 3.4% and intraclass correlation 
coefficient of 0.98.
Statistical Analysis
We summarized the continuous variables using median and in-
terquartile range, and categorical variables using percentage, by 
statin recommendation based on ATP III and ACC/AHA cholesterol 
guidelines. We tested the differences by statin recommendation us-
ing Student t test for normally distributed continuous variables and 
Wilcoxon rank-sum test for the rest. For categorical variables, χ2 
test was used. McNemar test, which examines the symmetry of a 
2×2 table was used to compare whether the recommendation for 
statin therapy using the 2013 ACC/AHA guidelines agreed with the 
recommendation using 2004 ATP III guidelines. χ2 test was also 
used to compare statin recommendation for each guideline (ATP 
III and ACC/AHA) based on the presence or absence of carotid 
plaque, and Cochran–Mantel–Haenszel test was used to compare 
statin recommendation for each guideline based on ordinal level of 
CIMT and its progression. We used ordinary least square regression 
to model the association of the ATP III Framingham and ACC/AHA 
ASCVD risk scores, as well as covariates with baseline CIMT, and 
linear mixed model with random intercept to model the association 
with CIMT progression. Additionally, we used Poisson regression 
models to estimate prevalence ratios (PRs) of plaque at baseline 
and plaque progression at follow-up and examine the association 
with baseline plaque and progression of plaque. A robust variance 
estimator was applied to adjust for potential overdispersion in the 
models. In all multivariable models, we adjusted for demographic 
factors (age, race, and sex). Cox proportional hazard models were 
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constructed to estimate the hazard ratio and examine the associa-
tion with all-cause mortality controlling for demographics and sig-
nificant covariates found in unadjusted models. All analyses were 
performed using SAS 9.4.
Results
Participant Characteristics
The baseline characteristics of the 352 HIV-infected partici-
pants in our study are shown in Table 1 stratified by whether 
statin therapy was recommended by the ATP III and ACC/
AHA cholesterol guidelines. Under both ATP III and ACC/
AHA guidelines, more HIV-infected adults were not recom-
mended for statin therapy (304 versus 48 for ATP III and 259 
versus 93 for ACC/AHA). For the ACC/AHA guidelines, 
HIV-infected participants who were recommended for statin 
therapy were older than those not recommended for statins 
(median, 53 versus 43 years) with more participants being 
black and fewer being white. Participants recommended for 
statin therapy also had higher systolic blood pressure (125 ver-
sus 120 mm Hg), longer duration of HIV infection (15 versus 
11 years), longer exposure to protease inhibitors (2.8 versus 
0.5 years), and more evidence of lipodystrophy (58% versus 
42%). Comorbidities and traditional risk factors were more 
common in those recommended for statin therapy, such as his-
tory of hypertension, diabetes mellitus, and cigarette smoking. 
Total cholesterol and triglycerides were higher, and HDL cho-
lesterol was lower in those recommended for statin therapy. 
On average, those recommended for statin therapy had higher 
number of Framingham risk factors, higher 10-year FRS, and 
higher 10-year ASCVD risk score. Similar baseline charac-
teristic differences were noted when comparing statin recom-
mendation for ATP III. Mean LDL cholesterol was higher in 
participants recommended for statin using ATP III, but dif-
ference in LDL cholesterol between statin recommendation 
groups was not observed using ACC/AHA guidelines. Death 
data were ascertained using Social Security Death Index and 
National Death Index registries. In the 13.5 years of follow-
up, 47 deaths occurred; of these, 2 were CVD, 11 because 
of HIV-related infections, 11 because of cancer, 6 because of 
liver or renal disease, 5 because of recreational drug overdose, 
2 because of physical assault, 2 because of respiratory disease, 
and 8 were unknown.
CIMT Characteristics at Baseline and Follow-Up
The median IMT at baseline was 0.85 mm (interquartile 
range, 0.72–1.04 mm), and 230 subjects (65.3%) had evidence 
of carotid plaque. The median duration of follow-up was 3.6 
years. At follow-up, median IMT progression was 0.052 mm 
per year (interquartile range, 0.025–0.095 mm per year), and 
71 subjects (58.2%), who did not have plaque at baseline, 
developed plaque.
Statin Recommendations by Guidelines
Using the ACC/AHA guidelines, 26.4% of our overall HIV-
infected population would be recommended statins as com-
pared with 13.6% using the ATP III guidelines (P<0.0001; 
Table 2). Among subjects without evidence of carotid plaque, 
15.6% would be recommended for statin therapy using 
ACC/AHA guidelines as compared with 6.6% using ATP III 
guidelines (P=0.025; Figure 1). Among subjects with evi-
dence of carotid plaque, 32.2% of subjects were recommended 
for statin based on ACC/AHA guidelines as compared with 
17.4% using the ATP III guidelines (P=0.0002).
At each quartile level of baseline IMT, the rate of statin 
recommendation was greater using the ACC/AHA guidelines 
as compared with the ATP III guidelines (Figure 2).
Association of Carotid Atherosclerosis and Clinical 
Characteristics
In unadjusted linear regression, the ATP III Framingham and 
ACC/AHA ASCVD risk scores were each strongly associ-
ated with baseline CIMT (0.01 mm per 10% increase in risk; 
P<0.001) and with CIMT progression (0.01 mm per year per 
10% increase in risk; P<0.001).
In a multivariable adjusted model controlling for race, sex, 
and ACC/AHA ASCVD risk score, baseline carotid plaque 
was independently associated with age (per decade; PR, 1.41; 
95% confidence interval [CI], 1.14–1.74; P=0.002), oppor-
tunistic infection (PR, 1.53; 95% CI, 1.18–1.99; P=0.001), 
pack per year of smoking (per 10 years; PR, 1.05; 95% CI, 
1.00–1.10; P=0.05), and LDL cholesterol (per doubling; PR, 
1.5; 95% CI, 1.13–2.00; P=0.005). Baseline mean CIMT was 
independently and positively associated with age (per decade; 
PR, 0.137; 95% CI, 0.071–0.203; P<0.001), hypertension 
(PR, 0.081; 95% CI, 0.005–0.156; P=0.037), LDL cholesterol 
(per doubling; PR, 0.107; 95% CI, 0.04–0.174; P=0.002), and 
high-sensitivity C-reactive protein (per doubling; PR, 0.02; 
95% CI, 0.001–0.039; P=0.038). Progression of CIMT was 
independently and positively associated with age (per decade; 
PR, 0.105; 95% CI, 0.04–0.169; P=0.002), hypertension (PR, 
0.077; 95% CI, 0.002–0.153; P=0.045), and LDL cholesterol 
(per doubling; PR, 0.112; 95% CI, 0.046–0.179; P=0.001).
In a multivariable Cox proportional hazard model adjusted 
by demographics, including ATP III FRS and ACC/AHA 
ASCVD risk score, and significant covariates, including body 
mass index, hepatitis C infection, nadir CD4 count, and CRP, 
baseline IMT (hazard ratio, 1.18; 95% CI, 1.05–1.33; P=0.005) 
and plaque (hazard ratio, 2.06; 95% CI, 1.02–4.08; P=0.037) 
were independent predictors of death (Table 3), whereas ATP 
III FRS and ACC/AHA ASCVD risk score were not.
Discussion
The ACC/AHA cholesterol guidelines recommend statin 
therapy for primary prevention in adults based on ASCVD 
risk scores that are calculated using traditional CVD risk fac-
tors.2 Although HIV-infected adults have an increased risk for 
atherosclerotic events, cardiac risk assessments created for 
the general population often underestimate CVD risk in the 
HIV-infected population and, therefore, fail to recommend 
preventive therapy, such as statins to HIV-infected adults. In 
our study of HIV-infected adults, we demonstrated the follow-
ing: (1) using the ACC/AHA guidelines, more subjects would 
be recommended for statin therapy as compared with ATP III 
guidelines; (2) both ACC/AHA and ATP III guidelines were 
strongly associated with CIMT and IMT progression in HIV; 
(3) among HIV-infected individuals with carotid plaque at 
baseline, >2 of 3 were not identified for statin therapy using 
either guideline; (4) baseline IMT and baseline presence of 
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Table 1. Baseline Characteristics (Median [Interquartile Range] or Percentage) of HIV-Infected Adults Stratified by Statin 
Recommendation Based on ATP III and ACC/AHA Cholesterol Guidelines
ATP III ACC/AHA
Statin (−)
(n=304)
Statin (+)
(n=48) P Value
Statin (−)
(n=259)
Statin (+)
(n=93) P Value
Demographics
  Age, y 45 (41–51) 49 (44–55) <0.001 43 (39–49) 53 (49–57) <0.001
  Race, %   0.162   0.01
   White 58 63  61 53  
   Black 29 17  25 35  
   Latino 10 15  12 5  
  Sex, %       
   Men 85 98 0.052 85 92 0.08
   Women 13 2  14 5  
  BMI, kg/m2 25 (23–28) 26 (23–28) 0.792 25.2 (23–29) 25.2 (23–28) 0.74
  SBP, mm Hg 121 (115–129) 122 (116–133) 0.263 120 (113–128) 125 (119–135) <0.001
  DBP, mm Hg 75 (68–80) 77 (69–84) 0.386 74 (68–80) 78 (72–83) 0.01
HIV factors
  HIV duration, y 12 (6–17) 15 (8–19) 0.04 11 (5–17) 15 (10–20) <0.001
  Nadir CD4, cells/uL 2 (0.6–3.6) 1.8 (0.8–3.1) 0.70 2.1 (0.6–0.38) 1.8 (0.9–3) 0.46
  Current CD4, cells/uL 4.4 (2.7–6.6) 4.3 (2.6–7.8) 0.43 4.6 (2.8–6.6) 4.2 (2.5–6.6) 0.45
  Treated, suppressed, % 40 56  41 45 0.34
   PI, y 0.6 (0–4.7) 3.3 (0–5.7) 0.05 0.5 (0–4.5) 2.8 (0–5.7) 0.05
   HAART, y 2.2 (0–5.5) 4.3 (1.3–7.2) 0.01 2.3 (0–5.6) 3.8 (0–6) 0.17
   Hepatitis C, % 28 6 0.001 24 28 0.44
   Lipodystrophy, % 43 67 0.002 42 58 0.01
Comorbidities, %
  Family history 22 21 0.891 23.6 16.1 0.14
  Hypertension 22 35 0.038 17.0 41.9 <0.001
  DM 2 17 <0.001 1 11 <0.001
  Any smoking 69 58 0.153 63.7 77.4 0.02
  Aspirin use 11 21 0.06 8.9 22.6 0.001
Laboratories
  Cholesterol, mg/dL 175 (149–198) 231 (213–242) <0.001 177 (150–205) 194 (166–217) 0.01
  LDL-C, mg/dL 99 (79–115) 154 (140–166) <0.001 103 (82–123) 106.5 (90–138) 0.06
  HDL-C, mg/dL 42 (35–51) 44 (37–50) 0.64 43 (36–51) 39 (30–48) 0.001
  Triglyceride, mg/dL 124 (81–209) 146 (99–222) 0.15 121 (80–193) 160 (98–283) 0.003
  hs-CRP, mg/L 1.7 (0.7–4) 2.1 (1–4.4) 0.34 1.7 (0.7–3.9) 1.9 (0.6–4.5) 0.78
  Glucose, mg/dL 87 (81–94) 89 (81–97) 0.31 86 (81–93) 89 (80–99) 0.10
Risk
  Fram risk factors 2 (1–3) 2 (1–3) 0.18 1 (1–2) 3 (2–3) <0.001
  10-y Fram risk score 3 (1–7) 9 (4–14) <0.001 3 (1–5) 10 (8–14) <0.001
  10-y ASCVD risk score 4.5 (2.6–7.8) 8.1 (3.6–11.8) 0.003 3.6 (2–5.1) 10.5 (8.7–13.4) <0.001
P values were based on Student t test for normally distributed continuous variables (age and total cholesterol), Mann–Whitney U test for all other skewed 
continuous variables, and χ2 test for categorial variables. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic 
cardiovascular disease; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; Fram, Framingham; HAART, highly active antiretroviral therapy; 
HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; PI, protease inhibitor; and SBP, 
systolic blood pressure.
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plaque were independently predictive of death in this cohort, 
whereas ACC/AHA and ATP III guidelines were not. Our find-
ings have significant clinical implications for HIV-infected 
individuals who, using traditional risk calculators, may not be 
identified to be at an elevated risk for ASCVD but who may be 
considered for statin therapy.
We found that HIV-infected adults who were recom-
mended for statin therapy by the ACC/AHA guidelines, were 
older, had a greater prevalence of traditional CVD risk factors, 
such as diabetes mellitus, hypertension, and smoking, higher 
blood pressures, and had more abnormal cholesterol profiles 
as compared with HIV-infected adults not recommended for 
statin therapy. Additionally, those recommended for statins 
had a greater prevalence of lipodystrophy and increased use 
of protease inhibitors, which suggest their contribution to 
traditional risk factors, such as dyslipidemia. As expected, 
Framingham and ACC/AHA ASCVD risk scores were higher 
in HIV-infected adults recommended for statin therapy as 
compared with those who were not. In unadjusted linear 
regression analysis, the Framingham and ASCVD risk scores 
were both strongly associated with CIMT and CIMT progres-
sion. In HIV-infected adults recommended for statin therapy 
by the ACC/AHA guidelines, 80% of subjects had carotid 
plaque. These results are consistent with previously published 
research documenting the association between traditional 
CVD risk factors and carotid atherosclerosis.11 Certain tradi-
tional risk factors, such as cigarette smoking, are more preva-
lent in the HIV-infected population and likely contribute to 
some of the observed increase in CVD risk and prevalence of 
carotid disease in the HIV-infected population.12 Similar to the 
general population, application of the ACC/AHA guidelines 
to HIV-infected adults who have elevated CVD risk based on 
the presence of traditional CVD risk factors may adequately 
identify those who may benefit from statin therapy.
Prior studies have shown that even after controlling for 
traditional risk factors, HIV-infected adults have increased 
CVD risk.13,14 Observational studies have reported ≈2-fold 
increase in CVD risk in HIV-infected adults as compared with 
matched uninfected controls15, and this risk remains even in 
the setting of treated suppressed HIV disease and younger 
age. HIV infection itself confers a risk similar to that of tra-
ditional risk factors.16 CVD risk-assessment tools, which are 
based primarily on traditional risk factors and intended for 
use in the general population, often fail to accurately iden-
tify elevated CVD risk observed in HIV-infected subjects.17 
The Framingham risk calculator and the ACC/AHA risk score 
underestimate actual rates of CVD in HIV by as much as 50% 
among individuals with an intermediate 5-year risk.18,19 In 
our study, despite the increase in the number of HIV-infected 
adults being recommended for statins, the ACC/AHA guide-
lines only recommended statin therapy to a minority of our 
subjects overall (26%) and failed to recommend statin in the 
majority of subjects with subclinical carotid atherosclerosis 
(68%). Additionally, although baseline IMT and plaque were 
shown to independently correlate with mortality, CVD risk 
scores by ATP III and ACC/AHA both failed to predict death 
in our HIV-infected cohort. In the general population, IMT is 
a strong predictor of CVD outcomes with a 1.18 relative risk 
for MI per 0.10 mm CIMT difference and a 1.32 relative risk 
for stroke per 1 standard deviation CIMT difference.20 Our 
group has previously reported that inflammatory biomarkers 
interleukin-6 and CIMT are independently predictive of all-
cause mortality among treated and suppressed HIV-infected 
individuals.21 Although the ACC/AHA guidelines rely on their 
ASCVD risk score to guide treatment recommendations, the 
risk calculator was not derived from and never validated in an 
HIV-infected cohort and, therefore, may underestimate CVD 
risk in HIV-infected adults.2 Also, although the guidelines did 
not endorse the use of carotid imaging to guide treatment rec-
ommendations, they did recognize that there are special popu-
lations who may require additional risk assessments beyond 
the ACC/AHA risk calculator. The results of our study are 
consistent with prior research demonstrating the failure of the 
ACC/AHA guidelines to recommend statin therapy in HIV-
infected adults who may have elevated CVD risk based on 
the presence of subclinical atherosclerosis.22 A smaller cohort 
of 108 HIV-infected adults without known ASCVD22 showed 
Table 2. Statin Recommendations by ACC/AHA and ATP III Guidelines
ATP III  
Not 
Recommended Recommended Total P Value
ACC/AHA Not Recommended 238 21 259 (73.6%) <0.0001
Recommended 66 27 93 (26.4%)  
Total 304 (86.4%) 48 (13.6%) 352  
ACC indicates American College of Cardiology; and AHA, American Heart Association.
Figure 1. Comparison of statin recommendation by ATP III and 
American College of Cardiology (ACC)/American Heart Asso-
ciation (AHA) guidelines based on the presence or absence of 
carotid plaque.
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that 74% of HIV-infected adults with evidence of subclinical 
high-risk morphology coronary plaque would not have had 
statin therapy using the ACC/AHA guidelines. These findings 
may extend to other populations who have elevated athero-
sclerotic risk that is not completely captured by traditional 
risk-assessment tools.
Beyond just increasing CVD risk, HIV infection is 
independently associated with the development of ath-
erosclerosis.9,14 Prior published data from our group have 
demonstrated that HIV-infected adults have greater CIMT 
at baseline and 1-year follow-up as compared with control 
subjects.9 Additionally, in the Study of Fat Redistribution 
and Metabolic Change (FRAM), HIV-infected adults had a 
mean CIMT that was 0.033 mm thicker than uninfected con-
trols after adjustment for traditional CVD risk factors and 
baseline characteristics (P=0.005).14 Although traditional 
risk factors play a role in the development of atherosclero-
sis in HIV-infected adults, multiple lines of evidence have 
shown that HIV-specific factors, such as chronic inflamma-
tion and immune activation, also can contribute to the devel-
opment of arterial disease.10,23,24 In a prior study, our group 
showed that high-sensitivity C-reactive protein levels were 
elevated at baseline in HIV-infected adults and were sig-
nificant predictors of progression of carotid atherosclerosis 
in the bifurcation region.10 In our current study, we found 
that opportunistic infections were independently associated 
with baseline carotid plaque, and high-sensitivity C-reactive 
protein levels were independently associated with baseline 
mean CIMT. The lower than expected prevalence of diabe-
tes mellitus and hypertension in our cohort also supports the 
possible contribution of HIV-related factors to the devel-
opment of carotid atherosclerosis. Accordingly, studies in 
HIV-infected populations suggest that noncalcified plaque 
may play a key role in HIV25 and that even in the absence of 
detectable coronary calcium, >1 of 3 HIV-infected individu-
als have markedly increased IMT, suggesting that imaging 
modalities, such as IMT, may be a more sensitive indicator of 
atherosclerosis in HIV.26
Although there are many studies documenting the benefit 
of statin therapy in reducing cardiovascular events in adults at 
elevated CVD risk, there are currently no data from random-
ized controlled trials documenting the benefit of statin ther-
apy specifically in a HIV-infected population with elevated 
risk of CVD; although a study is currently being conducted 
(NCT02344290). In a meta-analysis of 10 randomized con-
trolled trials of statin therapy that enrolled 70 388 non-HIV 
infected adults without established CVD, Brugts et al27 dem-
onstrated that treatment with statins significantly reduced the 
risk of all-cause mortality (odds ratio [OR], 0.88; 95% CI, 
0.81–0.96), major coronary events (odds ratio, 0.70; 95% 
CI, 0.61–0.81), and major cerebrovascular events (odds ratio, 
0.81; 95% CI, 0.71–0.93). Additionally, prior data suggest that 
there may be benefit in using statins in subjects with low FRSs 
but who have evidence of subclinical carotid atherosclerosis.28 
In the METEOR trial (Effect of Rosuvastatin on Progression 
of Cartid Intima-Media Thickness in Low-Risk Individuals 
With Subclinical Atherosclerosis: The Meteor Trial), 984 
subjects with low 10-year FRS (<10%) and elevated CIMT 
(1.2–3.5 mm) were randomized to rosuvastatin 40 mg daily or 
placebo. After 2 years of treatment, statin treatment was sig-
nificantly associated with less CIMT progression as compared 
with the placebo group (odds ratio, −0.0014; 95% CI, −0.0041 
to 0.0014 mm per year versus odds ratio, 0.0131; 95% CI, 
0.0087–0.0174 mm per year; P<0.001). Similar to the sub-
jects in METEOR, our HIV-infected cohort had a low mean 
10-year FRS of 4% but the majority (65.3%) having evidence 
of carotid plaque.
This was an observational study, and although we made 
every effort to adjust our analysis appropriately, unmeasured 
confounders may be present that were not accounted for. 
The number of deaths overall was small and the majority 
of deaths were not ASCVD-related in our cohort; however, 
despite this small number of deaths, we were able to dem-
onstrate a significant predictive value for CIMT and not the 
ASCVD or ATP III risk calculators. Although carotid ath-
erosclerosis may not be directly related to non-CVD deaths, 
we hypothesize that chronic inflammation and advanced 
immunodeficiency because of HIV infection may contribute 
to other non-AIDS conditions, including renal disease and 
malignancies. The observational design of our study along 
with small number of deaths does not allow us to draw defin-
itive conclusions on the relationship between carotid athero-
sclerosis and non-CVD deaths.
Table 3. Association of Risk Scores and IMT With All-Cause 
Mortality
 
Hazard 
Ratio 95% CI P Value
ATP III Framingham risk score 
(per 10% increment)
1.03 0.98–1.08 0.312
ACC/AHA ASCVD risk score (per 
10% increment)
1.03 0.97–1.09 0.296
Baseline IMT (per 10% 
increment)
1.18 1.05–1.33) 0.005
Baseline plaque (yes vs no) 2.06 1.04–4.08 0.037
Multivariable adjusted model that controls for age, race, sex, body mass 
index, hepatitis C status, nadir CD4 level, and C-reactive protein level. The 
variables were assessed separately after adjusting for covariates. ACC indicates 
American College of Cardiology; AHA, American Heart Association; ASCVD, 
atherosclerotic cardiovascular disease; and IMT, intima-media thickness.
Figure 2. Comparison of statin recommendation by ATP III and 
American College of Cardiology (ACC)/American Heart Associa-
tion (AHA) guidelines based on the level of carotid artery intima-
media thickness (CIMT). IMT indicates intima-media thickness.
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In summary, we found that although the application of 
the ACC/AHA cholesterol guidelines increased the number 
of HIV-infected adults recommended for statin therapy as 
compared with the ATP III guidelines, the majority of HIV-
infected adults with evidence of subclinical atherosclerosis 
were not recommended for statins. The independent associa-
tions found between (1) HIV-related factors and carotid ath-
erosclerosis and (2) carotid atherosclerosis, but not ASCVD 
risk scores, and mortality suggest that elevated CVD risk in 
the HIV-infected population may not be accurately captured 
using traditional risk-assessment tools. Future studies are 
needed to determine whether the assessment for subclinical 
atherosclerosis may help improve risk stratification in the HIV 
population and identify HIV-infected adults who may be con-
sidered for statin therapy.
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CLINICAL PERSPECTIVE
Although HIV is associated with increased cardiovascular risk, it is unknown whether cholesterol guidelines can appropri-
ately identify HIV-infected adults for statin treatment. We compared the 2013 American College of Cardiology/AHA and 
2004 ATP III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness 
and plaque. Although the American College of Cardiology/AHA guidelines recommended statins to a greater number of 
HIV-infected adults compared with the ATP III guidelines, both guidelines failed to recommend therapy in the majority of 
HIV-affected adults with carotid plaque. Baseline carotid atherosclerosis but not atherosclerotic cardiovascular disease risk 
scores was an independent predictor of mortality. HIV-related factors, such as the presence of opportunistic infections and 
elevated high-sensitivity C-reactive protein levels, were independently associated with carotid atherosclerosis. Using tradi-
tional risk calculators may fail to identify HIV-infected adults who are at elevated cardiovascular disease risk. HIV-specific 
guidelines that include detection of subclinical atherosclerosis may help to identify HIV-infected adults who are at increased 
cardiovascular disease risk and may be considered for statins therapy.
